Online inquiry

IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10757MR)

This product GTTS-WQ10757MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ADAMTSL5&ALB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Lama glama; Humanized
RefSeq NM_213604.3; NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 339366; 213
UniProt ID Q6ZMM2; P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10757MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15164MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ13955MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ12008MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ4805MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ4794MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ3242MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ12437MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ15161MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA T1h
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW